ニュース
Annual Congress, CureGene Pharmaceuticals ("CureGene") announced late-breaking preclinical results for its investigational liver-targeted thyroid hormone receptor beta (THR-β) prodrug, CG-0416.
Patients who stop using weight loss medications are likely to return to their baseline weight within two years, a new ...
Weightwatchers and bariatric surgery had limited effects on the obese brain, but GLP-1s like Ozempic may mean new hope in ...
The popularity of weight loss drugs has caused a shortage in recent years, but how effective are they at helping with food ...
A Brazilian influencer revealed her former boyfriend applied a weight loss medication to her body while she slept because he ...
Septerna's GPCR platform shows promise, but execution risks, funding needs, and competition suggest caution. Click here to ...
Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...
Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...
In a press release announcing the move, Novo Nordisk cited market challenges and its declining share price in a press release ...
For those preferring a drug-free approach to weight loss, research shows that certain nutrients and dietary strategies can naturally mimic the effects of semaglutides.
From marathon gym sessions and trendy detox teas to the latest GLP-1 injections, people will try just about anything to get ...
Lars Fruergaard Jorgensen, who has headed the pharmaceutical company for eight years, will step down after a period to ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する